Dr. De Carvalho is a senior scientist at Princess Margaret Cancer Centre and Associate Professor at the Department of Medical Biophysics at University of Toronto. Moreover, he holds the Canada Research Chair in Cancer Epigenetics and the Helen M Cooke endowed professorship. As recognition for his scientific excellence, dr. De Carvalho has received multiple awards, including the Canadian Cancer Society Bernard and Francine Dorval Prize, the CIHR new investigator salary award and the CIHR-ICR new Early Career Award in Cancer. His research was highlighted by ASCO in its annual report as one of the most important biomedical discoveries in oncology in 2012, by Nature Medicine (top 10 notable advances of 2015), NEJM (clinical implications of basic research: Epigenetic Modulators and the New Immunotherapies) and the Wall Street Journal. Dr. De Carvalho’s research program focuses on the translational aspects of cancer epigenetics. He is motivated by the fact that DNA methylation profiles are largely changed between normal tissue and cancer tissue in virtually all cancer types. His research program aims to understand whether cancer cells depend on this aberrant DNA methylation profile and whether it is amenable to therapeutic intervention. He is also interested in understanding whether it is possible to modulate an anti-tumor immune response using epigenetic therapy. His work provided the scientific basis of multiple clinical trials testing this combination. Finally, He is taking advantage of this massive cancer epigenetic reprogramming to develop tissue-based and blood-based (liquid biopsy) biomarkers for sub-group classification and cancer early detection.